Barbara S. Gillespie, MD, MMS, FASN

VP, Therapeutic Head of Nephrology at Labcorp Drug Development
Adjunct Professor at University of North Carolina, Division of Nephrology & Hypertension

Dr. Gillespie serves on the Board of Directors of the Kidney Health Initiative, a public-private partnership between the FDA and ASN with the mission of facilitating patient-centered innovation and clinical development for kidney disease. She also participates in the following KHI Workgroups: APOL1 Nephropathy, Endpoints for IgA Nephropathy/ FSGS/ C3G, Pediatric IgAN, and Barriers to CKD patient participation in CV Trials. Since joining industry in 2006, she has worked closely with many stakeholders and sponsors to support clinical development for devices and therapies across most indications in CKD and ESKD. She is on the Steering Committee for the NKF Patient Network (CKD Registry), and an invited participant or Workgroup Co-Chair on several NFK Scientific Workshops (Renal Endpoints 2018 & 2020, SGLT2-I), PREPARE-Nephrotic Syndrome, UNC/PCORI Stakeholder Ad Board for Building Research Capacity in Dialysis, and SONG Workgroups. She has enjoyed working on NephCure initiatives such as the Clinical Trial Collaborative (2018 Workgroup Co-Chair), Revolutionizing Rare Kidney Diseases, NS Specialists, and will also serve on NephCure’s imminent Coalition for Asian Community Outreach (CACO).

She completed her residency in internal medicine at the University of North Carolina and her nephrology fellowship at Duke University Medical Center, and until recently served as an Associate Medical Director at the local dialysis units and CKD clinics in the Raleigh Department of Corrections.

Durham, North Carolina